Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dicycloverine + mefenamic acid
- Development stage
- Unknown
- Lead developer
- Adorshea Bioceutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ADORTA-MF is a fixed-dose combination pharmaceutical product containing dicycloverine (also known as dicyclomine) and mefenamic acid. Dicycloverine is an antispasmodic agent that acts as a muscarinic acetylcholine receptor antagonist, effectively reducing smooth muscle contractions in the gastrointestinal and uterine tracts. Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) belonging to the fenamate class; it works by inhibiting the enzymes cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby decreasing the synthesis of prostaglandins that mediate pain and inflammation. This combination is primarily indicated for the symptomatic relief of spasmodic pain associated with conditions such as biliary colic, intestinal colic, and primary dysmenorrhea. It is developed and marketed by Adorshea Bioceutics.
- Brand names
- ADORTA-MF
- Other names
- dicyclomine + mefenamic aciddicycloverine hydrochloride + mefenamic acid
02
Targets
mAChR (Muscarinic acetylcholine receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on dicycloverine + mefenamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dicycloverine + mefenamic acid.